Celcuity's Annual Report Details FDA Priority Review for Gedatolisib, Extended Cash Runway

summarizeSummary

Celcuity's 2025 annual report confirms FDA Priority Review for gedatolisib, details significant clinical trial progress, and highlights successful capital raises that extend its cash runway through 2027, despite increased operating losses.

check_boxKey Events

• FDA Grants Priority Review for Gedatolisib NDA

  The FDA accepted Celcuity's New Drug Application (NDA) for gedatolisib in HR+/HER2- PIK3CA WT advanced breast cancer, granting it Priority Review with a PDUFA goal date of July 17, 2026. This follows the NDA submission in November 2025 and was previously announced on March 25, 2026.

• Increased Net Loss and R&D Expenses in 2025

  For the fiscal year ended December 31, 2025, Celcuity reported a net loss of $177.0 million, a 58% increase from $111.8 million in 2024. Research and development expenses rose by 39% to $145.0 million, reflecting increased clinical trial activities and commercial launch preparations, including a $5.0 million milestone payment to Pfizer.

• Secured Significant Financing to Extend Cash Runway

  The company raised $194.9 million net from a convertible notes offering in August 2025 and $91.6 million net from an equity offering in July 2025. Additionally, $27.7 million net was received from a Term D Loan in September 2025. These financings are expected to fund operations through 2027.

• Ongoing Clinical Trial Progress

  The Phase 3 VIKTORIA-1 trial's PIK3CA WT cohort reported positive detailed results in Q3/Q4 2025, with topline data for the PIK3CA MT cohort expected in Q2 2026. The Phase 3 VIKTORIA-2 trial's safety run-in was completed in Q1 2026, and a Phase 1b/2 trial (CELC-G-201) for prostate cancer is ongoing with updated results presented in October 2025.

auto_awesomeAnalysis

Celcuity's annual report for fiscal year 2025 provides a comprehensive update on its clinical pipeline and financial position. The reiteration of the FDA's Priority Review designation for gedatolisib, initially announced yesterday, is a critical regulatory milestone that significantly de-risks the lead candidate and sets a PDUFA goal date of July 17, 2026. While the company reported a substantial increase in net loss and R&D expenses, this is typical for a clinical-stage biotech advancing multiple trials. Successful financing activities, including convertible notes and an equity offering, have extended the cash runway through 2027, providing crucial liquidity for ongoing development and commercialization preparations. Investors should monitor the upcoming topline data for the VIKTORIA-1 PIK3CA MT cohort and the final Phase 3 study design for VIKTORIA-2.